Patent classifications
A61L27/50
IN VIVO BULKING AGENT, INJECTION COMPRISING SAME, AND PREPARATION METHOD THEREFOR
The present invention relates to an in-vivo bulking agent which can be used as a medicinal agent for prevention or treatment of at least one disease selected from the group consisting of urinary incontinence, fecal incontinence, and gastroesophageal reflux or as a filler for use in a plastic surgery procedure, and to a preparation method therefor. The in-vivo bulking agent can exhibit a bulking effect when injected into the body and particularly, is highly biocompatible because a first composition in which silicone particles are coated with a zwitterionic polymer having a surfactant property is introduced into a second composition, whereby the bulking agent can inhibit inflammatory reactions in vivo.
MEDICAL CALCIUM CARBONATE COMPOSITION, RELATED MEDICAL COMPOSITIONS, AND PRODUCTION METHODS THEREFOR
Provided is a medical calcium carbonate composition that highly satisfies 1) tissue affinity, 2) in vivo resorbability, 3) reactivity, and 4) mechanical strength required for medical materials to be implanted in vivo, a medical calcium phosphate composition, a medical carbonate apatite composition, a medical calcium hydroxide porous structure, a medical calcium sulfate setting granules, and a bone defect regeneration kit related to the medical calcium carbonate composition, and methods for producing these. The medical composition calcium carbonate that highly satisfies the above described elements, and related medical compositions can be produced by controlling the polymorph or structure of calcium carbonate.
NANOFIBER- AND NANOWHISKER-BASED TRANSFECTION PLATFORMS
Described herein are electrospun core-shell fibers that include (i) a central core that is electrically conductive having an exterior surface, wherein the core comprises a first polymer and an electroconductive material; (ii) a shell adjacent to the exterior surface of the core, the shell comprising a second polymer; and (iii) one or more bioactive agents in the shell. In one aspect, the fibers are electrospun fibers. Additionally, described herein are methods for making and using the core-shell fibers.
PLASMA ION PROCESSING OF SUBSTRATES
A method for plasma ion processing is described, including flowing a gas into porous material; and exposing the gas to a pulsed electric field whilst the gas is in the pores. The pulsed electric field ionises the gas to generate a plasma. The method may additionally include exposing the porous material to a gas so as to generate functionality. The method may additionally include exposing the functionalised porous material to a functional species so as to covalently attach said functional species to the surfaces of the pores.
ADDITIVE MANUFACTURING OF HYDROGEL TUBES FOR BIOMEDICAL APPLICATIONS
Embodiments of the present disclosure include methods of simultaneously manufacturing two or more hydrogel constructs (e.g., tubular hydrogel constructs). In some embodiments, the method comprises one or more of the following steps: providing a vat comprising a bio-ink composition containing one or more monomers and/or one or more polymers; applying electromagnetic radiation from an electromagnetic radiation source to cure a layer of the hydrogel constructs (e.g., tubular hydrogel constructs); and applying electromagnetic radiation from the electromagnetic radiation source one or more additional times to produce one or more additional layers of the hydrogel constructs (e.g., tubular hydrogel constructs).
Additive Manufacturing of Channels
A method is disclosed for 3D printing of soft polymeric material such as a hydrogel or elastomer for scaffolds or devices with embedded channels with tunable shape and size such as a channel inner diameter). The method utilizes extrusion based printing of polymer solutions usually referred as direct ink writing (DIW) or BioPlotting, and requires sequential printing of a photocurable polymer solution, herein, referred as the matrix material, and a sacrificial polymer solution that may dissolve in an aqueous media.
COMPOSITE ORTHOPAEDIC PROSTHESIS AND METHOD OF MAKING THE SAME
An orthopaedic prosthesis includes a femoral component comprising polymeric materials. The polymeric materials may include a polyaromatic ether or a polyacetal. The orthopaedic prosthesis may include a component having an articular layer and a support layer adjacent the articular layer. The support layer may include a reinforcement fiber. The orthopaedic prosthesis may be a knee prosthesis.
Additive manufacturing of channels
A method is disclosed for 3D printing of soft polymeric material such as a hydrogel or elastomer for scaffolds or devices with embedded channels with tunable shape and size such as a channel inner diameter). The method utilizes extrusion based printing of polymer solutions usually referred as direct ink writing (DIW) or BioPlotting, and requires sequential printing of a photocurable polymer solution, herein, referred as the matrix material, and a sacrificial polymer solution that may dissolve in an aqueous media.
Medical material and method for preparing from biological tissue
Medical material and a method for preparing a biological tissue for a medical application are provided. The material is useful as a sealing element in a heart valve prosthesis. A method includes decellularizing the biological tissue by decellularizing solution to obtain an acellular extracellular matrix, solubilizing the extracellular matrix of the biological tissue, and crosslinking collagen fibers of the solubilized extracellular matrix.
OPHTHALMIC DEVICES
A method for preparing an ophthalmic device for slowing, inhibiting or preventing myopia progression involves contacting an ophthalmic device having one or more reactive functional groups with one or more red-light blocking compounds having one or more reactive functional groups complementary to the one or more reactive functional groups of the ophthalmic device in a basic solution for a time period sufficient to covalently bond at least one reactive functional group of the ophthalmic device with at least one reactive functional group of the one or more red-light blocking compounds. The one or more red-light blocking compounds block greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm.